AstraZeneca acquisition brings drug to fill rare disease gap left by Takeda

The latest stories trending on MedCity News.

Editor's Pick

Top Story AstraZeneca Acquisition Brings Drug to Fill a Rare Disease Gap Left by Takeda AstraZeneca is acquiring Amolyt Pharma to get eneboparatide, a drug in Phase 3 development for treating hypoparathyroidism. Takeda Pharmaceutical markets the only FDA-approved treatment for this rare disease, but the Japanese pharmaceutical giant plans to stop making the drug. Sponsored Content How Quantum Health is Solving the Challenges Facing Employers Presented by Quantum Health and MedCity News Zane Burke, Quantum Health CEO, highlighted the value healthcare navigation companies can offer self-insured employers and the recent announcement of their partnership with Vanderbilt Health Affiliated Network. How are startups going to survive 2024? After a challenging 1H24, the balance of the year promises to be exciting as the value of these novel solutions becomes increasingly more evident." INVEST 2024 Speaker, Michael Greeley Co-Founder and General Partner of Flare Capital Partners Register Now and Save $300 [ends 3/29]

Featured News

A First for Fatty Liver: FDA Approves Madrigal Pharma NASH Drug The FDA has approved Madrigal Pharmaceuticals drug Rezdiffra as a treatment for the fatty liver disease NASH (also called MASH). It's the first treatment for the chronic condition, which has been growing in prevalence. HiLabs Secures $39M for AI-Powered Data Management Solutions HiLabs' Series B funding round was led by Denali Growth Partners and Eight Roads Ventures and included participation from F-Prime Capital. In total, HiLabs has raised about $41 million. GE HealthCare & Mass General Brigham Have a Plan to Accelerate Their AI Research At HIMSS, GE HealthCare and Mass General Brigham announced that they are integrating foundation models into their collaborative AI research and development. Foundation models could help developers create healthcare AI tools "10 times faster than in the past," according to Parminder Bhatia, GE HealthCare's chief AI officer. GLP-1s Alone Are Not the Answer to America's Obesity and Chronic Illness Crises Obesity/overweight is a significant causal factor in chronic illness and cancer. Weight loss can help people with obesity/overweight avoid and/or manage chronic illness. GLP-1s cause weight loss. So, are GLP-1s the answer to America's obesity and chronic illness crises? Not if we overlook a key problem at the heart of both challenges: lack of access to nutritious food in the land of plenty.

Resources

Debunked: No-Fluff Healthcare News Show Episode 2 of our Debunked show is now available. Editor-in-Chief Arundhati Parmar and co-host Samir Batra discuss unfair hospital pricing and what CA is trying to do starting April 1 to prevent too many large healthcare transactions involving CA healthcare entities that they could deem anticompetitive in nature.  Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe